Breast cancer drug 'too expensive' for NHS

A drug that can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.

Kadcyal can give patients with HER2-positive breast cancer which has spread to other parts of the body and where initial treatments have failed an additional six months of life.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

View all 5 updates ›

Breast cancer drug manufacturer 'could have done more'

The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.

Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:

Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.

We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.

– Sir Andrew Dillon

More top news